Skip to main content
Premium Trial:

Request an Annual Quote

Chr. Hansen Taps CLC Bio, Genostar Bioinformatics Suites for In-House NGS Analysis Pipeline


Food ingredients firm Chr. Hansen has implemented bioinformatics suites from CLC Bio and Genostar as part of its in-house pipeline for analyzing next-generation sequence data.

In addition to internally developed software, the company is using several CLC Bio products, including CLC Genomics Server and CLC Genomics Workbench, to assemble its NGS data. The company is also using Genostar's Metabolic Pathway Builder and KoriBlast for "gene-oriented" analyses such as gene finding, gene annotation, comparative genomics, and metabolic mapping.

Chr. Hansen chose to develop some parts of its pipeline internally because it could not find tools on the market that were suited to its needs, Martin Pedersen, Chr. Hansen's senior manager of physiology and innovation, told BioInform.

For example, the company has developed bespoke algorithms to check for foreign DNA contamination in samples as well as to check data quality.

The company decided to keep its NGS analyses in house in order to maintain a hands-on approach and ensure that its pace of research isn't slowed by outsourcing, he said

The pipeline will be used to create metabolic maps of nearly 200 lactic acid bacteria genome sequences, to search for genes encoding antibiotic resistance and other characteristics, to compare strains, and to generate pan-genomes, among other tasks.

The company has no plans to commercialize any of its in-house software components but might publish a paper on its DNA contaminant-detection algorithm, Pedersen said.

With is headquarters in Hørsholm, Denmark, and 2,300 employees in more than 30 countries, Chr. Hansen develops natural ingredients for the food, nutritional, pharmaceutical, and agricultural industries.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.